Authors :
Dr Irfan Ali; Dr Azizullah; Dr Rashkehinna; Dr Najm Ul Hassan shafi; Dr Javeria Isram; Dr Salim tauri
Volume/Issue :
Volume 7 - 2022, Issue 11 - November
Google Scholar :
https://bit.ly/3IIfn9N
Scribd :
https://bit.ly/3jip5cd
DOI :
https://doi.org/10.5281/zenodo.7588252
Abstract :
Treatment of Hepatitis C has remarkably changed
worldwide with the introduction of Directly Acting Agents
(DAA’s). Multiple regimens have been employed for the
treatment of hepatitis C patients. In 2018, the regimen of
sofosbuvir and velpatasvir (SOF/VEL) was approved by
World Health Organization to be used.The aim of this
study was to assess the efficacy of SOF/VEL in the
treatment of chronic hepatitis C patients in a tertiary care
hospital in Pakistan.
Materials and Methods
This was a prospective and single arm interventional
study conducted from July 2021 to July 2022 at Holy
Family Hospital, Rawalpindi after getting ethical approval
from Rawalpindi Medical University. Chronic hepatitis C
patients regardless of having complications such as
hepatocellular carcinoma, decompensated liver disease
and previous treatment history were recruited after taking
informed consent. All patients were give single tablet
combination of SOF/VEL for period of 12 weeks after
which sustained virological response (SVR) was measured.
Data were collected on a structured proforma and was
entered and analyzed in IBM SPSS 23.0.
Keywords :
Sofosbuvir, Velpatasvir, Hepatitis C, sustained virological response, Pakistan.
Treatment of Hepatitis C has remarkably changed
worldwide with the introduction of Directly Acting Agents
(DAA’s). Multiple regimens have been employed for the
treatment of hepatitis C patients. In 2018, the regimen of
sofosbuvir and velpatasvir (SOF/VEL) was approved by
World Health Organization to be used.The aim of this
study was to assess the efficacy of SOF/VEL in the
treatment of chronic hepatitis C patients in a tertiary care
hospital in Pakistan.
Materials and Methods
This was a prospective and single arm interventional
study conducted from July 2021 to July 2022 at Holy
Family Hospital, Rawalpindi after getting ethical approval
from Rawalpindi Medical University. Chronic hepatitis C
patients regardless of having complications such as
hepatocellular carcinoma, decompensated liver disease
and previous treatment history were recruited after taking
informed consent. All patients were give single tablet
combination of SOF/VEL for period of 12 weeks after
which sustained virological response (SVR) was measured.
Data were collected on a structured proforma and was
entered and analyzed in IBM SPSS 23.0.
Keywords :
Sofosbuvir, Velpatasvir, Hepatitis C, sustained virological response, Pakistan.
